Filing Details

Accession Number:
0001818382-23-000119
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-21 18:07:15
Reporting Period:
2023-08-17
Accepted Time:
2023-08-21 18:07:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818382 Humacyte Inc. HUMA Biological Products, (No Disgnostic Substances) (2836) 851763759
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1878024 Ayabudge Llc 2525 East North Carolina Highway 54
Durham NC 27713
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-08-17 570,174 $3.68 9,420,562 No 4 S Direct
Common Stock Disposition 2023-08-18 626,979 $3.57 8,793,583 No 4 S Direct
Common Stock Disposition 2023-08-21 602,443 $3.39 8,191,140 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.
  2. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.